Kalaris Therapeutics, Inc.
KLRSHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeKalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. The company carries a $44.5M market cap, placing it firmly in the micro-cap category. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Market Cap
$44.5M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-1.13
EPS (TTM)
$-2.02
EPS (Fwd)
$-1.65
ROE
-79.9%
ROA
-31.0%
Cash
$93.5M
Total Debt
$1.4M
Free CF
-$26.2M
52W Change
-61.5%
Annual Financials
Cash vs Debt
Where KLRS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, KLRS finished 57.37% below its 150-day moving average ($4.48) and 66.55% below its 200-day moving average ($5.71). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KLRS overbought or oversold?
At the October 20, 2026 close, KLRS's RSI(14) was 13.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Kalaris Therapeutics, Inc. holds $93.5M in cash against $1.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$26.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -79.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Kalaris Therapeutics, Inc. and its sector.